The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

• Status: Active, not recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: COMPASS Pathways
• Treatments: Psilocybin

Criteria

Inclusion Criteria:

• Diagnosis of TRD

Exclusion Criteria:

• Other comorbidities